BiotechTube
HAWK Biosystems

HAWK Biosystems

Barcelona, Spain· Est.
hawkbiosystems.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $10.5M

Overview

HAWK Biosystems is a private, pre-revenue diagnostics company founded in 2018, pioneering a novel spatial biology platform. Its core technology, QF-Pro®, uses an amplified FRET-FLIM assay to quantify functional protein interactions and modifications at nanoscopic resolution in FFPE tissues, a capability unachievable with existing methods. The company is initially targeting the immuno-oncology market to improve immunotherapy patient selection and has established partnership programs for development and commercialization. HAWK operates as a platform technology provider with a clear path toward companion diagnostic development.

Oncology

Technology Platform

QF-Pro® is a patented spatial biology platform based on an amplified FRET-FLIM assay. It uses a two-site immunoassay format to quantify functional protein events (e.g., interactions, modifications) at 1-10nm resolution directly in FFPE tissue samples, providing high-specificity, multiplexed, and quantitative data.

Funding History

2
Total raised:$10.5M
Series A$8M
Seed$2.5M

Opportunities

The primary opportunity lies in addressing the critical unmet need for better predictive biomarkers in immuno-oncology by quantifying functional protein interactions, which could significantly improve patient response rates to costly immunotherapies.
Additionally, the platform's core technology is applicable across numerous disease areas involving protein dysfunction, offering substantial market expansion potential through research and diagnostic partnerships.

Risk Factors

Key risks include the challenge of driving adoption of a technically complex platform in a competitive spatial biology market and the significant cost and time required for robust clinical validation to achieve regulatory approval.
The company also faces execution risk as a pre-revenue startup dependent on securing funding and forming successful strategic partnerships to scale.

Competitive Landscape

HAWK competes in the spatial biology and multiplex proteomics market against established players like Akoya Biosciences (PhenoCycler, PhenoImager) and NanoString (GeoMx DSP), which focus on protein or RNA expression quantification. Its key differentiation is the direct measurement of protein *function* via proximity, but it faces competition from simpler, more entrenched technologies and must prove its clinical utility justifies the added complexity.

More companies in Diagnostics & Precision Medicine →More companies in Spain →